The [almost] unbelievable relationship between “big pharma” and gray-market peptides
Over the past year, we have returned several times to gray-market peptides—what the evidence actually shows for compounds like BPC-157, CJC-1295, and others—and what we know, or…
DO
By Daniel Okafor · Regulatory Correspondent
Oct 17 07:01 ETSource: Peter Attia MD
From the source
Read at peterattiamd.comThe [almost] unbelievable relationship between “big pharma” and gray-market peptides
Over the past year, we have returned several times to gray-market peptides—what the evidence actually shows for compounds like BPC-157, CJC-1295, and others—and what we know, or more often do not know, about their safety and efficacy.
